Compare TG Therapeutics Inc (TGTX) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vanguard S&P 500 ETF — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while Vanguard S&P 500 ETF trades at $687.23. Which is the better fit depends on your goals.
| TGTX | VOO | |
|---|---|---|
Market Cap | $8.26B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $59.06 | $698.29 |
52-Week Low | $26.39 | $571.45 |
Enterprise Value | $8.50B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
VOO, the Vanguard S&P 500 ETF, trades at $682.20, down slightly by 0.14% over 24 hours. Technical indicators show a bearish trend with moving averages signaling caution, though oscillators are neutral. The ETF recently surpassed $1.0 trillion in assets under management, reflecting strong institutional confidence. A dividend of $1.96 is scheduled for payment on June 30, 2026.
The outlook for VOO is mixed; its low-cost, diversified exposure to the S&P 500 offers long-term growth potential, but current technical weakness and elevated market valuations pose near-term risks. Investors should weigh the ETF's historical resilience against potential volatility from economic shifts or sector rotations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
